Revenue Components (Tables)

9 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

The following table provides information about the Company’s revenues (in thousands):


	Three Months Ended December 31,				Nine Months Ended December 31,
	2022		2021		2022		2021
Revenues:
Product revenue, net:
ORGOVYX	$	48,724	$	24,393	$	128,077	$	53,535
MYFEMBREE	10,527		2,429		20,929		4,133
Accord product supply and royalties	387		—		387		—
Richter product supply and royalties	1,784		2,446		3,327		4,217
Total product revenue, net	61,422		29,268		152,720		61,885
Pfizer collaboration revenue:
Amortization of upfront payment	20,974		20,974		62,922		62,922
Amortization of regulatory milestones	8,333		4,198		46,103		16,931
Total Pfizer collaboration revenue	29,307		25,172		109,025		79,853
Accord license and milestone revenue	5,000		—		55,000		—
Richter license and milestone revenue	4,000		—		4,300		31,667
Other revenue	500		—		500		—
Total revenues	$	100,229	$	54,440	$	321,545	$	173,405

Summary Of Categories Of Discounts And Allowances

The activities and ending balances for each significant category of discounts and allowances (which constitutes variable consideration) for the nine months ended December 31, 2022 were as follows (in thousands):


	Reserve -government and other incentives		Chargebacks and administrative fees		Returns		Sales Discounts		Total
Balance as of March 31, 2022	$	13,734	$	2,628	$	3,028	$	486	$	19,876
Provision related to sales in the current year	86,741		22,550		3,062		4,331		116,684
Adjustments related to prior year sales	891		(762)		—		—		129
Credits and payments made during the current year	(75,014)		(19,988)		(12)		(4,148)		(99,162)
Balance as of December 31, 2022	$	26,352	$	4,428	$	6,078	$	669	$	37,527

The total reserves described above are summarized as components of the Company’s unaudited condensed consolidated balance sheets as follows (in thousands):


	December 31, 2022		March 31, 2022
Reduction of accounts receivable, net	$	669	$	486
Component of accrued expenses and other current liabilities	36,858		19,390
Total revenue-related reserves	$	37,527	$	19,876